Harvard Pilgrim Health Care, Inc.

Harvard Pilgrim Health Care, Inc. Office Of Sponsored Programs Division, a non-profit tax-exempt healthcare research organization headquartered in Canton, Massachusetts, delivers post-market medical product safety surveillance, pharmacoepidemiology, and public health research services to the Food and Drug Administration and the Centers for Disease Control and Prevention as a prime contractor on over $1.16 billion in combined federal awards. The organization competes in full-and-open procurements without set-aside designations and operates the majority of its federal work through prime contract and grant positions (74% of recent awards), with a secondary subcontracting footprint (26% of awards).

The organization's federal capability portfolio centers on FDA Sentinel System operations—including maintenance of the Active Risk Identification and Analysis (ARIA) system, real-world claims and electronic health record data integration, and post-market surveillance infrastructure—complemented by CDC vaccine safety monitoring through the Vaccine Safety Datalink program and epidemiological research across NIH institutes. Concrete contract work includes a $31.7 million sole-source bridge contract awarded March 29, 2026, by the FDA for continuation of Sentinel 2.0 operations through September 2027, encompassing program leadership, FHIRMA compliance support, and risk identification system maintenance. Other recent prime awards comprise a $22.1 million time-and-materials delivery order for FDA Sentinel health research and data analysis (extended March 28, 2025), a $25.7 million firm fixed-price delivery order from FDA for Sentinel System ARIA operations and real-world evidence management (September 2024), and a $6.7 million cost-reimbursable delivery order from CDC for Vaccine Safety Datalink operations through September 2027 (September 2022). The organization also holds two wide-reaching CDC IDIQs—one valued at $149 million for vaccine safety datalink services and another at $99 million for the Safe Healthcare, Epidemiology, and Prevention Research Development Program (SHEPheRD).

Customer concentration is heavily skewed toward HHS agencies. The top five funding customers account for 47% of recent awards by count, with the FDA anchoring $1.16 billion in combined potential value across 75 awards and CDC Pittsburgh commanding $700.9 million across 22 awards. NIH awards (22 across all institutes, with 21 from the National Heart, Lung, and Blood Institute alone) and AHRQ funding round out the federal research portfolio. The dollar concentration is even sharper than the count concentration—FDA and CDC together represent the substantial majority of the organization's federal potential value, making this vendor strategically tied to these two agencies' post-market surveillance and vaccine safety agendas.

The organization operates five major parent contract vehicles: an HHSF223200910006I indefinite delivery contract (19 task orders, $108.9 million combined value), an HHSA29020050033I IDC (12 task orders, $13.5 million), an HHSF223201400030I IDC (12 task orders, $112.1 million), and two others carrying smaller task order counts. These vehicles are the operative mechanism through which FDA, CDC, and other HHS agencies issue delivery orders for ongoing surveillance and research services.

Activity shows strong growth through 2024 (four awards in 2022 rising to 39 in 2024), moderating to 25 and 15 awards in 2025 and 2026 respectively. Twenty-six awards carrying combined potential value of $75.6 million will reach ultimate completion within the next twenty-four months, triggering significant recompete exposure on Sentinel System follow-on procurements and CDC vaccine safety monitoring continuity contracts.

SCI-reported invoicing on federal service contracts above the $150,000 threshold reached $46.5 million cumulatively across FY2022–FY2024 (not the organization's total federal revenue, which includes grants, products, and goods contracts). Invoiced amounts grew from $2.6 million in FY2022 to $24.8 million in FY2023 and held at $19.2 million in FY2024. The organization delivered roughly 51 FTEs to federal service contracts in FY2023 and 50 FTEs in FY2024, signaling stable workforce deployment. Government-paid rates on SCI contracts ranged from a 10th percentile of $137.85 per hour to a median of $180.78 per hour to a 90th percentile of $324.03 per hour, reflecting mixed staffing with epidemiologists, biostatisticians, and data managers alongside junior research support.

Across SCI-reportable prime contracts, subs accounted for an average of 9% of contractor hours, with 19 named subcontractors engaged across the portfolio. Teksystems, Inc. appears as a named subcontractor for IT staffing support on a CDC ICRA program task order. The organization also subcontracts on select prime awards: it performs work under Brigham & Women's Hospital on medication risk evaluation and mitigation strategy research, under the University of Florida on emerging infection surveillance during pregnancy, and under Lee Medical Case Review, LLC on evidence-based newborn screening reviews. The org's sub engagement is modest, indicating predominantly self-performed delivery of epidemiological analysis, data integration, and research management—a capability profile aligned with its status as an established health services research institute with in-house biostatistics and clinical expertise.

Federal grant awards reflect a research focus on maternal and child health, prevention science, and health disparities. HPHC is recipient on grants from NIH institutes including the National Institute on Aging (reproductive aging and chronic disease, $706 thousand, May 2026), the National Institute of Environmental Health Sciences (early-life environmental exposures and kidney function, $3.8 million, April 2026), the National Heart, Lung, and Blood Institute (metabolites in childhood asthma, $1.51 million, September 2025; nutrition enhancement in home-visiting, $1.68 million cooperative agreement, September 2025), the National Institute of Diabetes and Digestive and Kidney Diseases (real-world data validity for diabetes research, awarded March 2025), and the National Institute of Mental Health (multiple awards on telehealth policy impact, insurance access, and LGBT health disparities). HPHC also receives NIH grants on vaccine safety, antibiotic stewardship, and HIV prevention research. The organization serves as sub-recipient on dozens of prime grants from universities (Duke, Brigham & Women's Hospital, Boston University, Emory, Stanford, Johns Hopkins, Cleveland Clinic) where HPHC researchers contribute biostatistical expertise, data management, and population medicine leadership. This grant footprint demonstrates the organization's recognized standing in health services research, epidemiology, and implementation science across NIH's mission agencies.